XBI has “moved higher a record 12 of 13 months,” Mizuho healthcare sector specialist Jared Holz wrote Friday.

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

One of the platforms recently attracting global biopharmaceutical companies is the ‘Blood-Brain Barrier (BBB) Shuttle.’ The ...

Kardigan (KARD) didn’t just raise $400 million. The heart-drug developer sent a new signal to biotech investors about what ...

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

The acquisition should close in the third quarter and values the biotech at $135.11 per share in cash.

The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...

AbbVie proved big pharma will pay up for late-stage immunology, and three names keep surfacing on Wall Street's who’s-next ...